Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H24N2O7.2ClH |
| Molecular Weight | 405.271 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.[H][C@@]12O[C@H](C)CC(=O)[C@]1(O)O[C@]3([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]3([H])O2
InChI
InChIKey=FOGDPGQSHLLYIK-XYQGXRRISA-N
InChI=1S/C14H24N2O7.2ClH/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14;;/h5,7-13,15-16,18-20H,4H2,1-3H3;2*1H/t5-,7-,8+,9+,10+,11-,12-,13+,14+;;/m1../s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H24N2O7 |
| Molecular Weight | 332.3496 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.jwatch.org/ac200604260000004/2006/04/26/spectinomycin-discontinued-treatment-gonorrhea
Curator's Comment: description was created based on several sources, including
http://www.jwatch.org/ac200604260000004/2006/04/26/spectinomycin-discontinued-treatment-gonorrhea
Spectinomycin is an antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae. In vitro studies have shown spectinomycin to be active against most strains of Neisseria gonorrhoeae (minimum inhibitory concentration <7.5 to 20 mcg/mL). Footprint studies indicate that spectinomycin exerts regional effects on ribosomal structure. Spectinomycin hydrochloride is an inhibitor of protein synthesis in the bacterial cell; the site of action is the 30S ribosomal subunit. The antibiotic is not significantly bound to plasma protein. Spectinomycin was discovered 1961. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. This antibiotic is no longer available in the United States. Pfizer has discontinued distribution of spectinomycin (Trobicin) in the U.S. The drug continues to be distributed outside the U.S.
CNS Activity
Originator
Sources: Applied microbiology (1961), 9, 524-8.
Curator's Comment: https://books.google.es/books?id=5Fv0BwAAQBAJ&pg=PA47&lpg=PA47&dq=spectinomycin+was+discovered+1961&source=bl&ots=tz5daI3o3n&sig=HdeWzppPEz7i1UZ7Y_zxMM7qsFo&hl=ru&sa=X&ved=0ahUKEwjX1YWN9NDPAhXE0hoKHc8mB5cQ6AEIJDAB#v=onepage&q=spectinomycin%20was%20discovered%201961&f=false
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2363135 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | TROBICIN Approved UseTROBICIN Sterile Powder is indicated in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae. Men and women with known recent exposure to gonorrhea should be treated as those known to have gonorrhea. Launch Date4.7088001E10 |
|||
| Curative | TROBICIN Approved UseTROBICIN Sterile Powder is indicated in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae. Men and women with known recent exposure to gonorrhea should be treated as those known to have gonorrhea. Launch Date4.7088001E10 |
|||
| Curative | TROBICIN Approved UseTROBICIN Sterile Powder is indicated in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of Neisseria gonorrhoeae. Men and women with known recent exposure to gonorrhea should be treated as those known to have gonorrhea. Launch Date4.7088001E10 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100 μg/mL |
2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
SPECTINOMYCIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
460 μg × h/mL |
2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
SPECTINOMYCIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.7 h |
2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
SPECTINOMYCIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100% |
2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
SPECTINOMYCIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains. | 1973 Sep |
|
| Screening for new compounds with antiherpes activity. | 1984 Oct |
|
| Spectinomycin and cholestatic jaundice. | 1985 Nov |
|
| [Decreased incidence of postgonococcal urethritis following minocycline treatment compared to penicillin/spectinomycin]. | 1986 Jun 1 |
|
| Comparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sources. | 1990 Jul |
|
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
| Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda. | 1993 Jun |
|
| Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. | 1993 Sep 24 |
|
| In-vitro activities of aminoglycoside-aminocyclitols against mycobacteria. | 1997 Jul |
|
| [Regeneration of cybrid Lycopersicon peruvianum x (Solanum rickii) plants with genetically transformed chloroplasts]. | 2005 Nov-Dec |
|
| [Stable transformation of Solanum rickii chloroplast DNA]. | 2005 Sep-Oct |
|
| Antimicrobial and toxicological evaluation of the leaves of Baissea axillaries Hua used in the management of HIV/AIDS patients. | 2006 Jun 21 |
|
| [Somatic hybrids among transgenic Solanum tuberosum and transplastomic Solanum rickii]. | 2008 Jul-Aug |
|
| [Biodegradation of pyridine by Shinella zoogloeoides BC026]. | 2008 Oct |
|
| Complete PHB mobilization in Escherichia coli enhances the stress tolerance: a potential biotechnological application. | 2009 Aug 31 |
|
| Experimental and computational validation of models of fluorescent and luminescent reporter genes in bacteria. | 2010 Apr 29 |
|
| [E-test quantitative determination for evaluating Neisseria gonorrhoeae resistance]. | 2010 Oct-Dec |
|
| Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. | 2011 Aug |
|
| Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. | 2014 Feb |
Sample Use Guides
Adults (Men and Women)—Inject 5 mL intramuscularly for a 2-gram dose. This is also the recommended dose for patients being treated after failure of previous antibiotic therapy
Route of Administration:
Intramuscular
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:59:34 UTC 2023
by
admin
on
Fri Dec 15 14:59:34 UTC 2023
|
| Record UNII |
296JEI210Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 522.2120
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
||
|
NCI_THESAURUS |
C2363
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
296JEI210Z
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
PRIMARY | |||
|
DTXSID9045429
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
PRIMARY | |||
|
64740
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
PRIMARY | |||
|
C90690
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
PRIMARY | |||
|
21736-83-4
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
PRIMARY | |||
|
244-554-3
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
PRIMARY | |||
|
100000092045
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
PRIMARY | |||
|
248616
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
PRIMARY | |||
|
9216
Created by
admin on Fri Dec 15 14:59:34 UTC 2023 , Edited by admin on Fri Dec 15 14:59:34 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |